Lamivudine treatment in patients with HBV-related hepatocellular carcinoma-using an untreated, matched control cohort

Cheng Yu Piao, Shin Ichi Fujioka, Yoshiaki Iwasaki, Kozo Fujio, Toshihiko Kaneyoshi, Yasuyuki Araki, Kuniaki Hashimoto, Tomonori Senoh, Ryo Terada, Tomohiro Nishida, Haruhiko Kobashi, Kohsaku Sakaguchi, Yasushi Shiratori

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Lamivudine is widely used to treat patients with hepatitis B. However, the outcomes in patients with hepatocellular carcinoma (HCC) treated with lamivudine have not been established. This study was conducted to evaluate the outcomes of lamivudine treatment for patients with HCC using an untreated, matched control group. Thirty patients with controlled HCC orally received lamivudine. As controls, 40 patients with HCC who were not treated with lamivudine and matched for clinical features were selected. The lamivudine-treated and untreated groups were compared with respect to changes in liver function, HCC recurrence, survival, and cause of death. In the lamivudine-treated group, there was significant improvement in the Child-Pugh score at 24 months after starting treatment, while no improvement was observed in the untreated group. There was no significant difference in the cumulative incidence of HCC recurrence and survival between the groups. However, there was a significant difference in the cumulative incidence of death due to liver failure (P = 0.043). A significant improvement in liver function was achieved by lamivudine treatment, even in patients with HCC. These results suggest that lamivudine treatment for patients with HCC may prevent death due to liver failure. Further prospective randomized studies using a larger number of patients are required. Copyright

Original languageEnglish
Pages (from-to)217-224
Number of pages8
JournalActa Medica Okayama
Volume59
Issue number5
Publication statusPublished - Oct 2005

Fingerprint

Lamivudine
Hepatocellular Carcinoma
Liver
Therapeutics
Liver Failure
Recurrence
Survival
Incidence
Hepatitis B
Cause of Death
Research Design
Prospective Studies
Control Groups

Keywords

  • Child-Pugh score
  • Liver failure
  • Recurrence
  • Resistant mutant
  • Survival

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Piao, C. Y., Fujioka, S. I., Iwasaki, Y., Fujio, K., Kaneyoshi, T., Araki, Y., ... Shiratori, Y. (2005). Lamivudine treatment in patients with HBV-related hepatocellular carcinoma-using an untreated, matched control cohort. Acta Medica Okayama, 59(5), 217-224.

Lamivudine treatment in patients with HBV-related hepatocellular carcinoma-using an untreated, matched control cohort. / Piao, Cheng Yu; Fujioka, Shin Ichi; Iwasaki, Yoshiaki; Fujio, Kozo; Kaneyoshi, Toshihiko; Araki, Yasuyuki; Hashimoto, Kuniaki; Senoh, Tomonori; Terada, Ryo; Nishida, Tomohiro; Kobashi, Haruhiko; Sakaguchi, Kohsaku; Shiratori, Yasushi.

In: Acta Medica Okayama, Vol. 59, No. 5, 10.2005, p. 217-224.

Research output: Contribution to journalArticle

Piao, CY, Fujioka, SI, Iwasaki, Y, Fujio, K, Kaneyoshi, T, Araki, Y, Hashimoto, K, Senoh, T, Terada, R, Nishida, T, Kobashi, H, Sakaguchi, K & Shiratori, Y 2005, 'Lamivudine treatment in patients with HBV-related hepatocellular carcinoma-using an untreated, matched control cohort', Acta Medica Okayama, vol. 59, no. 5, pp. 217-224.
Piao, Cheng Yu ; Fujioka, Shin Ichi ; Iwasaki, Yoshiaki ; Fujio, Kozo ; Kaneyoshi, Toshihiko ; Araki, Yasuyuki ; Hashimoto, Kuniaki ; Senoh, Tomonori ; Terada, Ryo ; Nishida, Tomohiro ; Kobashi, Haruhiko ; Sakaguchi, Kohsaku ; Shiratori, Yasushi. / Lamivudine treatment in patients with HBV-related hepatocellular carcinoma-using an untreated, matched control cohort. In: Acta Medica Okayama. 2005 ; Vol. 59, No. 5. pp. 217-224.
@article{68ce3932709f489a9ca185d668f058e0,
title = "Lamivudine treatment in patients with HBV-related hepatocellular carcinoma-using an untreated, matched control cohort",
abstract = "Lamivudine is widely used to treat patients with hepatitis B. However, the outcomes in patients with hepatocellular carcinoma (HCC) treated with lamivudine have not been established. This study was conducted to evaluate the outcomes of lamivudine treatment for patients with HCC using an untreated, matched control group. Thirty patients with controlled HCC orally received lamivudine. As controls, 40 patients with HCC who were not treated with lamivudine and matched for clinical features were selected. The lamivudine-treated and untreated groups were compared with respect to changes in liver function, HCC recurrence, survival, and cause of death. In the lamivudine-treated group, there was significant improvement in the Child-Pugh score at 24 months after starting treatment, while no improvement was observed in the untreated group. There was no significant difference in the cumulative incidence of HCC recurrence and survival between the groups. However, there was a significant difference in the cumulative incidence of death due to liver failure (P = 0.043). A significant improvement in liver function was achieved by lamivudine treatment, even in patients with HCC. These results suggest that lamivudine treatment for patients with HCC may prevent death due to liver failure. Further prospective randomized studies using a larger number of patients are required. Copyright",
keywords = "Child-Pugh score, Liver failure, Recurrence, Resistant mutant, Survival",
author = "Piao, {Cheng Yu} and Fujioka, {Shin Ichi} and Yoshiaki Iwasaki and Kozo Fujio and Toshihiko Kaneyoshi and Yasuyuki Araki and Kuniaki Hashimoto and Tomonori Senoh and Ryo Terada and Tomohiro Nishida and Haruhiko Kobashi and Kohsaku Sakaguchi and Yasushi Shiratori",
year = "2005",
month = "10",
language = "English",
volume = "59",
pages = "217--224",
journal = "Acta Medica Okayama",
issn = "0386-300X",
publisher = "Okayama University",
number = "5",

}

TY - JOUR

T1 - Lamivudine treatment in patients with HBV-related hepatocellular carcinoma-using an untreated, matched control cohort

AU - Piao, Cheng Yu

AU - Fujioka, Shin Ichi

AU - Iwasaki, Yoshiaki

AU - Fujio, Kozo

AU - Kaneyoshi, Toshihiko

AU - Araki, Yasuyuki

AU - Hashimoto, Kuniaki

AU - Senoh, Tomonori

AU - Terada, Ryo

AU - Nishida, Tomohiro

AU - Kobashi, Haruhiko

AU - Sakaguchi, Kohsaku

AU - Shiratori, Yasushi

PY - 2005/10

Y1 - 2005/10

N2 - Lamivudine is widely used to treat patients with hepatitis B. However, the outcomes in patients with hepatocellular carcinoma (HCC) treated with lamivudine have not been established. This study was conducted to evaluate the outcomes of lamivudine treatment for patients with HCC using an untreated, matched control group. Thirty patients with controlled HCC orally received lamivudine. As controls, 40 patients with HCC who were not treated with lamivudine and matched for clinical features were selected. The lamivudine-treated and untreated groups were compared with respect to changes in liver function, HCC recurrence, survival, and cause of death. In the lamivudine-treated group, there was significant improvement in the Child-Pugh score at 24 months after starting treatment, while no improvement was observed in the untreated group. There was no significant difference in the cumulative incidence of HCC recurrence and survival between the groups. However, there was a significant difference in the cumulative incidence of death due to liver failure (P = 0.043). A significant improvement in liver function was achieved by lamivudine treatment, even in patients with HCC. These results suggest that lamivudine treatment for patients with HCC may prevent death due to liver failure. Further prospective randomized studies using a larger number of patients are required. Copyright

AB - Lamivudine is widely used to treat patients with hepatitis B. However, the outcomes in patients with hepatocellular carcinoma (HCC) treated with lamivudine have not been established. This study was conducted to evaluate the outcomes of lamivudine treatment for patients with HCC using an untreated, matched control group. Thirty patients with controlled HCC orally received lamivudine. As controls, 40 patients with HCC who were not treated with lamivudine and matched for clinical features were selected. The lamivudine-treated and untreated groups were compared with respect to changes in liver function, HCC recurrence, survival, and cause of death. In the lamivudine-treated group, there was significant improvement in the Child-Pugh score at 24 months after starting treatment, while no improvement was observed in the untreated group. There was no significant difference in the cumulative incidence of HCC recurrence and survival between the groups. However, there was a significant difference in the cumulative incidence of death due to liver failure (P = 0.043). A significant improvement in liver function was achieved by lamivudine treatment, even in patients with HCC. These results suggest that lamivudine treatment for patients with HCC may prevent death due to liver failure. Further prospective randomized studies using a larger number of patients are required. Copyright

KW - Child-Pugh score

KW - Liver failure

KW - Recurrence

KW - Resistant mutant

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=31344450073&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31344450073&partnerID=8YFLogxK

M3 - Article

VL - 59

SP - 217

EP - 224

JO - Acta Medica Okayama

JF - Acta Medica Okayama

SN - 0386-300X

IS - 5

ER -